APVO442 is a distinct PSMA x CD3 targeted bispecific candidate designed to optimize T cell fitness and distribution to solid tumorsRebecca Gottschalk,Robert Miller,Brian Woodruff,Ashly Lucas,Elizabeth Haglin,Peter Pavlik,Michelle H. Nelson,Hilario J. RamosCANCER RESEARCH(2022)引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要